YMB YM Bio.'b'ser1

    YM BioSciences Annual and Special Meeting Update

 

    MISSISSAUGA, ON, Dec. 14 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), is pleased to announce that at the annual and special meeting of

shareholders of the Company held December 8th 2004, all of the resolutions

proposed in Management's Proxy Circular sent to shareholders on November 17th

2004 were duly passed.

    A complete copy of Management's Proxy Circular is available at

www.sedar.com.

 

    About YM BioSciences

    YM BioSciences Inc. is a cancer drug development company. Its lead drug,

tesmilifene, is a small molecule chemopotentiator (for taxanes and

anthracyclines) currently undergoing a pivotal Phase III trial in metastatic

breast cancer. Tesmilifene has completed a previous Phase III trial with

positive results. In addition to tesmilifene, the Company is developing an

EGFr humanized monoclonal antibody that is being tested in glioma and

pancreatic cancer in Phase II trials, has completed Phase II trials in head &

neck cancer, and is expected to enter a Phase III trial in 2005. A GnRH  

anti-cancer vaccine is in earlier stage clinical trials.

 

    Except for historical information, this press release may contain 

forward-looking statements, which reflect the Company's current expectation

regarding future events. These forward-looking statements involve risk and

uncertainties, which may cause but are not limited to, changing market

conditions, the successful and timely completion of clinical studies, the

establishment of corporate alliances, the impact of competitive products and

pricing, new product development, uncertainties related to the regulatory

approval process and other risks detailed from time to time in the Company's

ongoing quarterly and annual reporting.

 

    For further information: Enquiries: James Smith, The Equicom Group Inc.,

Tel. (416) 815-0700 x 229, Email: jsmith(at)equicomgroup.com; Carolyn McEwen,

YM BioSciences Inc., Tel. (905) 629-9761, Fax (905) 629-4959, Email:

ir(at)ymbiosciences.com

    (YMBA YM. YMI)

 



END

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jun 2024 to Jul 2024

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jul 2023 to Jul 2024